STSS (Sharps Technology) Debt-to-Revenue : N/A (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Sharps Technology Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Sharps Technology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $3.76 Mil. Sharps Technology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.00 Mil. Sharps Technology's annualized Revenue for the quarter that ended in Dec. 2024 was $0.00 Mil.

Sharps Technology Debt-to-Revenue Historical Data

The historical data trend for Sharps Technology's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sharps Technology Debt-to-Revenue Chart

Sharps Technology Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Revenue

N/A

Sharps Technology Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Revenue	Get a 7-Day Free Trial												N/A	N/A	N/A	N/A	N/A

Competitive Comparison of Sharps Technology's Debt-to-Revenue

For the Medical Instruments & Supplies subindustry, Sharps Technology's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sharps Technology's Debt-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sharps Technology's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Sharps Technology's Debt-to-Revenue falls into.

Save Embed

;

Save Embed

;

Sharps Technology Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Sharps Technology's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(3.764	+	0)	/	N/A
	=	N/A

Sharps Technology's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(3.764	+	0)	/	0
	=	N/A

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2024) Revenue data.

Sharps Technology Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Sharps Technology's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Sharps Technology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sharps Technology Inc (NAS:STSS) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

105 Maxess Road, Suite 124, Melville, NY, USA, 11747

Website

https://www.sharpstechnology.com

Sharps Technology Inc is a medical device company. It offers syringes and other safety products. Sharps provensa, Securgard, and Sologard are ultra-low waste smart safety syringes are designed to eliminate potentially infectious and accidental needlestick injuries.

Executives

Robert Michael Hayes	director, officer: Chief Executive Officer	75 BROOKSHIRE DRIVE, YOUNGSVILLE NC 27596
Andrew R. Crescenzo	officer: Chief Financial Officer	C/O ENZO BIOCHEM, 527 MADISON AVENUE, NEW YORK NY 10022
Timothy James Ruemler	director	3311 RIVERPARK CT., BENITA SPRINGS FL 34134
Alan R. Blackman	director, officer: CIO and COO	11502 ROBLES DR. REPP PLACE, TEMPLE TERRACE FL 33617
Paul K Danner	director
Soren Bo Christiansen	director	4059 SPRING VALLEY ROAD, DOYLESTOWN PA 18902
Brenda Baird Simpson	director	7336 PRAIRIE STAR COURT,, PARKER CO 80134
Jason L. Monroe	director	14527 LINDALE ROSE LANE, HUMBLE TX 77379
Barry Boris Berler	officer: CTO and Inventor	77 HERZL STREET, RAMAT GAN L3 5244352